Roche Holding AG (RHHBF)
USD 303.32
(0.0%)
USD 303.32
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 25.4 Billion CHF | 17.88% |
| 2022 | 21.55 Billion CHF | -16.14% |
| 2021 | 25.7 Billion CHF | 165.41% |
| 2020 | 9.68 Billion CHF | 1.86% |
| 2019 | 9.5 Billion CHF | -21.36% |
| 2018 | 12.08 Billion CHF | -15.11% |
| 2017 | 14.24 Billion CHF | -21.72% |
| 2016 | 18.19 Billion CHF | -6.8% |
| 2015 | 19.52 Billion CHF | -11.16% |
| 2014 | 21.97 Billion CHF | 50.05% |
| 2013 | 14.64 Billion CHF | -27.0% |
| 2012 | 20.06 Billion CHF | -12.78% |
| 2011 | 22.99 Billion CHF | -18.49% |
| 2010 | 28.21 Billion CHF | -29.41% |
| 2009 | 39.97 Billion CHF | 4939.47% |
| 2008 | -826 Million CHF | -126.55% |
| 2007 | 3.11 Billion CHF | -38.19% |
| 2006 | 5.03 Billion CHF | -7.52% |
| 2005 | 5.44 Billion CHF | -14.37% |
| 2004 | 6.35 Billion CHF | -36.52% |
| 2003 | 10.01 Billion CHF | -47.09% |
| 2002 | 18.92 Billion CHF | -8.13% |
| 2001 | 20.59 Billion CHF | 8.07% |
| 2000 | 19.05 Billion CHF | -14.44% |
| 1999 | 22.27 Billion CHF | 22.89% |
| 1998 | 18.12 Billion CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 29.61 Billion CHF | 0.0% |
| 2024 Q1 | 31.35 Billion CHF | 23.4% |
| 2023 Q2 | 21.66 Billion CHF | -5.07% |
| 2023 FY | 25.4 Billion CHF | 17.88% |
| 2023 Q3 | 25.18 Billion CHF | 16.23% |
| 2023 Q4 | 25.4 Billion CHF | 0.89% |
| 2023 Q1 | 22.82 Billion CHF | 5.9% |
| 2022 Q4 | 21.55 Billion CHF | 0.69% |
| 2022 FY | 21.55 Billion CHF | -16.14% |
| 2022 Q1 | 24.75 Billion CHF | -3.7% |
| 2022 Q2 | 23.43 Billion CHF | -5.32% |
| 2022 Q3 | 21.4 Billion CHF | -8.66% |
| 2021 Q4 | 25.7 Billion CHF | 1.22% |
| 2021 Q3 | 25.39 Billion CHF | 153.65% |
| 2021 Q2 | 10.01 Billion CHF | -10.9% |
| 2021 Q1 | 11.23 Billion CHF | 16.03% |
| 2021 FY | 25.7 Billion CHF | 165.41% |
| 2020 Q1 | 12.5 Billion CHF | 31.49% |
| 2020 FY | 9.68 Billion CHF | 1.86% |
| 2020 Q3 | 9.36 Billion CHF | -16.93% |
| 2020 Q4 | 9.68 Billion CHF | 3.41% |
| 2020 Q2 | 11.27 Billion CHF | -9.82% |
| 2019 Q3 | 9.16 Billion CHF | -33.96% |
| 2019 Q4 | 9.5 Billion CHF | 3.71% |
| 2019 FY | 9.5 Billion CHF | -21.36% |
| 2019 Q2 | 13.88 Billion CHF | -6.57% |
| 2019 Q1 | 14.85 Billion CHF | 22.91% |
| 2018 Q1 | 15.42 Billion CHF | 8.32% |
| 2018 Q3 | 12.11 Billion CHF | -21.49% |
| 2018 FY | 12.08 Billion CHF | -15.11% |
| 2018 Q2 | 15.42 Billion CHF | 0.0% |
| 2018 Q4 | 12.08 Billion CHF | -0.18% |
| 2017 Q4 | 14.24 Billion CHF | -0.12% |
| 2017 FY | 14.24 Billion CHF | -21.72% |
| 2017 Q3 | 14.25 Billion CHF | -19.27% |
| 2017 Q2 | 17.66 Billion CHF | 0.0% |
| 2017 Q1 | 17.66 Billion CHF | -2.91% |
| 2016 Q2 | 21.99 Billion CHF | 0.0% |
| 2016 Q1 | 21.99 Billion CHF | 12.69% |
| 2016 Q3 | 18.19 Billion CHF | -17.27% |
| 2016 Q4 | 18.19 Billion CHF | -0.04% |
| 2016 FY | 18.19 Billion CHF | -6.8% |
| 2015 FY | 19.52 Billion CHF | -11.16% |
| 2015 Q2 | 20.85 Billion CHF | 0.0% |
| 2015 Q4 | 19.52 Billion CHF | -0.03% |
| 2015 Q3 | 19.52 Billion CHF | -6.38% |
| 2015 Q1 | 20.85 Billion CHF | -5.08% |
| 2014 Q1 | 14.9 Billion CHF | 1.8% |
| 2014 Q3 | 21.98 Billion CHF | 47.46% |
| 2014 Q2 | 14.9 Billion CHF | 0.0% |
| 2014 FY | 21.97 Billion CHF | 50.05% |
| 2014 Q4 | 21.97 Billion CHF | -0.04% |
| 2013 FY | 14.64 Billion CHF | -27.0% |
| 2013 Q2 | 17.81 Billion CHF | 0.0% |
| 2013 Q4 | 14.64 Billion CHF | -0.27% |
| 2013 Q3 | 14.68 Billion CHF | -17.59% |
| 2013 Q1 | 17.81 Billion CHF | -11.19% |
| 2012 Q4 | 20.06 Billion CHF | 0.0% |
| 2012 Q2 | 22.44 Billion CHF | 0.0% |
| 2012 FY | 20.06 Billion CHF | -12.78% |
| 2011 Q2 | 24.17 Billion CHF | 0.0% |
| 2011 FY | 22.99 Billion CHF | -18.49% |
| 2011 Q4 | 22.99 Billion CHF | 0.0% |
| 2010 FY | 28.21 Billion CHF | -29.41% |
| 2010 Q2 | 34.46 Billion CHF | 0.0% |
| 2010 Q4 | 28.21 Billion CHF | 0.0% |
| 2009 Q4 | 39.97 Billion CHF | 0.0% |
| 2009 Q2 | 48.67 Billion CHF | 0.0% |
| 2009 FY | 39.97 Billion CHF | 4939.47% |
| 2008 Q2 | 1.53 Billion CHF | 0.0% |
| 2008 FY | -826 Million CHF | -126.55% |
| 2008 Q4 | -826 Million CHF | 0.0% |
| 2007 Q2 | 3.02 Billion CHF | 0.0% |
| 2007 FY | 3.11 Billion CHF | -38.19% |
| 2007 Q4 | 3.11 Billion CHF | 0.0% |
| 2006 Q4 | 5.03 Billion CHF | 0.0% |
| 2006 FY | 5.03 Billion CHF | -7.52% |
| 2005 FY | 5.44 Billion CHF | -14.37% |
| 2004 FY | 6.35 Billion CHF | -36.52% |
| 2003 FY | 10.01 Billion CHF | -47.09% |
| 2002 FY | 18.92 Billion CHF | -8.13% |
| 2001 FY | 20.59 Billion CHF | 8.07% |
| 2000 FY | 19.05 Billion CHF | -14.44% |
| 1999 FY | 22.27 Billion CHF | 22.89% |
| 1998 FY | 18.12 Billion CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | -11.676% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 15.313% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 1693.812% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | -160149.779% |
| Novartis AG | 12.95 Billion USD | -96.11% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 15070.987% |